|
The Affymax board of directors is made up of individuals with significant
experience starting, building and financing biotechnology companies.
Their experience brings breadth and depth from many vantage points
of the biotechnology and pharmaceutical industries.
R. Lee Douglas
Independent Biotechnology Consultant and Visiting Scholar, University of California, Berkeley
Nicholas Galakatos, Ph.D. (Lead Director)
General Partner, MPM BioVentures II and BioVentures III, L.L.C.
Christi van Heek
Managing Director, BIO POINT Group
Kathleen LaPorte
Managing Director, New Leaf Venture Partners
Keith Leonard
President and CEO, Kythera Biopharmaceuticals
Ted W. Love, M.D.
Chairman and CEO, Nuvelo, Inc.
Arlene M. Morris
President and CEO, Affymax, Inc.
Daniel K. Spiegelman
Senior Vice President and CFO, CV Therapeutics, Inc.
John P. Walker
Chairman and CEO, Novacea, Inc.
R. Lee Douglas
Independent Biotechnology Consultant and Visiting Scholar, University of California, Berkeley
Mr. Douglas was a co-founder of COR Therapeutics, Inc. While at COR, Mr. Douglas served in a number of key management positions, including as its original CEO. Since 1998, Mr. Douglas has been an independent consultant to biotechnology companies. He was a member of the founding teams of both Portola Pharmaceuticals, Inc., where he continues as an advisor, and Five Prime Therapeutics, Inc., where he serves on its board of directors.
Top
Nicholas Galakatos, Ph.D. (Lead Director)
General Partner, MPM BioVentures II and BioVentures III, L.L.C.
Dr. Galakatos is a General Partner of MPM BioVentures II and BioVentures III, LLC. He has over 21 years of investing and operating experience in the biotechnology and pharmaceutical industries. Prior to joining MPM in 2000 Dr. Galakatos was Vice President of New Business at Millennium Pharmaceuticals (NASDAQ: MLNM) where he co-founded Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was also Chairman. Prior to Millennium he was an Associate at Venrock Associates focusing on early stage biotechnology investments. Prior to Venrock he was Head of Molecular Biology Research at Novartis (formerly Ciba). He holds a Ph.D. in chemistry from MIT and a BA from Reed College. In addition to Affymax, Dr. Galakatos also serves on the Boards of Aerovance, Alinea, Aveo, Critical Therapeutics (NASDAQ:CRTX), Hypnion and Portola.
Top
Christi van Heek
Managing Director, BIO POINT Group
Ms. van Heek is Managing Director of BIO POINT Group, a company
which she founded and is focused on global commercialization, sales,
marketing and business development. Ms. van Heek also serves on
the board of directors for Visioneering Corporation. From 1991 to
2003, Ms. van Heek served in various roles at Genzyme, most recently
as corporate officer and president, Therapeutics Division. In addition,
she has held various sales and marketing positions at Genentech,
Inc. and Caremark/HHCA. Ms. van Heek holds a B.S.N. from the University
of Iowa and received her M.B.A. from Lindenwood University in St.
Louis.
Top
Kathleen LaPorte
Managing Director, New Leaf Venture Partners
Ms. LaPorte, along with other members of the Sprout Group healthcare team, founded New Leaf Venture Partners (NLV Partners) in July 2005. NLV Partners invests primarily in firms focused on clinical-stage biopharmaceutical products, early-stage medical devices and molecular diagnostics. In addition, NLV Partners continues to manage the existing $800 million healthcare technology portfolio of Sprout Group. Ms. LaPorte joined the Sprout Group in 1993 and became a General Partner in 1994. Between 1987 and 1993, she was a Principal at Asset Management Company, a venture capital firm focused on early-stage investments. Previously, she was a financial analyst with The First Boston Corporation. Ms. LaPorte received an M.B.A. from Stanford University Graduate School of Business (Arjay Miller Scholar) and a B.S., summa cum laude, Phi Beta Kappa, from Yale University.
Top
Keith Leonard
President and CEO, Kythera Biopharmaceuticals
Mr. Leonard currently serves as President and CEO of Kythera Biopharmaceuticals,
a privately held company focused on aesthetic medicine which he
founded in 2005. Prior to Kythera, Mr. Leonard served 13 years in
various roles at Amgen, Inc., most recently as senior vice president,
Amgen Europe from 2001 to 2004. Mr. Leonard holds a an M.B.A. from
the University of California, Los Angeles; an M.S. in engineering
from the University of California, Berkeley; a B.A. in history from
the University of Maryland; and a B.S. in engineering from the University
of California, Los Angeles.
Top
Ted W. Love, M.D.
Chairman and CEO, Nuvelo, Inc.
Dr. Love is Chairman of the board of directors of Nuvelo, Inc., a publicly traded biopharmaceutical company engaged in developing innovative drugs for acute cardiovascular and cancer therapy. He joined Nuvelo in 2001 as President and Chief Executive Officer and became Chairman of the Board in September 2005. Dr. Love joined Nuvelo from Theravance, Inc., where he served as Senior Vice President of Development. Previously, he spent six years at Genentech, Inc., where he held a number of senior management positions in medical affairs and product development and served as chairman of Genentech’s Product Development Committee. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development, including Herceptin®, Rituxan®, and TNKase®. Dr. Love also serves as a member of the boards of directors of Predix Pharmaceuticals, Inc., Santarus, Inc., and the California Healthcare Institute. In addition, he serves on the California Independent Citizens’ Oversight Committee (ICOC), the 29-member board that oversees the $3 billion allocated to stem cell research authorized by Proposition 71. Dr. Love earned his bachelor’s degree in molecular biology from Haverford College and his medical degree from Yale Medical School.
Top
Arlene M. Morris
President and CEO, Affymax, Inc.
Ms. Morris brings significant expertise in the development of strategic partnerships, marketing and operations to Affymax. She has more than 25 years of management experience from Johnson & Johnson, Scios Inc., Coulter Pharmaceutical, Inc. and most recently Clearview Projects. Ms. Morris joined Affymax from Clearview Projects, where she was the President and CEO. Clearview Projects is an advisory firm that counsels biopharmaceutical and biotechnology companies on strategic transactions. While at Coulter, she completed numerous transactions including the $1 billion merger between Coulter and Corixa and a contractual joint venture with GlaxoSmithKline (GSK) for Bexxar® valued in excess of $200 million. Previously, Ms. Morris was the Vice President of Business Development at Scios Inc. where she completed several high-profile transactions including one of the first biotech profit-sharing deals for a late-stage product. From 1977 through 1993, Ms. Morris held various management and executive positions at Johnson & Johnson in sales, marketing, new product development and business development, holding the position of Vice President of Business Development for McNeil Pharmaceutical from 1988 to 1993. She received her B.A. degree in Biology and Chemistry from Carlow College and studied marketing at Western New England College. Ms. Morris also serves on the board of directors for MediciNova, Inc., a specialty pharmaceutical company, and the Biotechnology Industry Organization (BIO).
Top
Daniel K. Spiegelman
Senior Vice President and CFO, CV Therapeutics, Inc.
Mr. Spiegelman is Senior Vice President and Chief Financial Officer of CV Therapeutics, Inc., a publicly traded biopharmaceutical company that is focused on applying molecular cardiology to the discovery, development, and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. He joined CV Therapeutics in January 1998 as Vice President and CFO. Previously, he was employed by Genentech, Inc., where he held a number of positions in the treasury department, including Treasurer. He holds a B.A. in economics from Stanford University and an M.B.A. from Stanford Graduate School of Business. Mr. Spiegelman currently serves as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. He previously served as a director for Xcyte Therapies, Inc. before its merger with Cyclacel in March 2006.
Top
John P. Walker
Chairman and CEO, Novacea, Inc.
Mr. Walker currently serves as interim CEO of Novacea, Inc., a publicly traded biopharmaceutical company focused on developing novel cancer therapies. He also serves as chairman of the boards of directors of Renovis, KAI Pharmaceuticals, Guava Technologies, and Saegis Pharmaceuticals. In addition, he serves on the boards of directors for Geron and several privately-held biotechnology companies. During his career, he has served as CEO or interim CEO of a number of companies, including chairman and CEO of Bayhill Therapeutics; interim CEO of KAI Pharmaceuticals; interim CEO of Guava Technologies; and chairman and interim CEO of Centaur Pharmaceuticals, Inc. From 1993 to 2001, he was chairman, CEO, and a director of Axys Pharmaceuticals Inc. and its predecessor company Arris Pharmaceutical Corporation. Before his association with Arris, he was the chairman and CEO of Vitaphore Corporation, a biomaterials company that was sold to Union Carbide Chemical and Plastics Company Inc. His other experience includes serving as a venture partner with Morgan Stanley Venture Partners and as an investment advisor to MDS Capital Corporation. Mr. Walker began his career with American Hospital Supply Corporation, where he served in a variety of general management, sales, and marketing positions, most recently serving as president of the American Hospital Company. He received a B.A. in history from the State University of New York at Buffalo and is a graduate of the Advanced Executive Program, J. L. Kellogg Graduate School of Management at Northwestern University.
Top |
